Steve, I suggest that shareholders would like to know WHY YOU CONTINUE TO OPERATE THE "CARDIAC" AND "VASCULAR" TISSUE COST CENTERS. WHY, WHY, WHY DO YOU DO IT? It appears that these two cost centers are "ZERO", or at best "NEAR ZERO", "net operating income" cost centers. The margins from these two cost centers don't seem to materially improve much over time either, so are shareholders on a train to nowhere?
These cost centers have a potential liability tail too, flash back to Brian Lykins in 2001. It was the tissue write offs and related tissue liability issues that almost bankrupted CRY back in the 2001-2003 period. These two cost centers appear to waste a lot of employee time too, time that could presumably be redirected to something with better profitability.
Also, the "FDA Warning Letter" was replete with comments pertaining to "cardiac" and "vascular" tissue matters.
STEVE, YOU NEVER NEVER EVER ANSWER THE TISSUE PROFITABILITY QUESTION.
STEVE, ARE "AFRAID" TO TELL SHAREHOLDERS THE "TRUTH" ABOUT THE "LACK OF PROFITABILITY" AT THESE TWO COST CENTERS?
IF THERE ARE GOOD REASONS FOR CONTINUING THE CARDIAC AND VASCULAR TISSUE LINES, THEN PLEASE EXPLAIN TO SHAREHOLDERS WHAT THESE REASONS ARE. Don't B S the shareholders either, because all they want is an simple answer that tells them the "TRUTH".